Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT01957956 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Giant Cell Glioblastoma
Glioblastoma
Gliosarcoma

Interventions

OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
DRUG: Temozolomide

Sponsor

Mayo Clinic